{"id":7822,"date":"2026-11-09T15:47:27","date_gmt":"2026-11-09T12:47:27","guid":{"rendered":"https:\/\/mikhailinvest.com\/multi-node-supply-chains-are-the-future-in-a-multi-polar-pharma-world\/"},"modified":"2026-11-09T15:47:27","modified_gmt":"2026-11-09T12:47:27","slug":"multi-node-supply-chains-are-the-future-in-a-multi-polar-pharma-world","status":"publish","type":"post","link":"https:\/\/mikhailinvest.com\/zh\/multi-node-supply-chains-are-the-future-in-a-multi-polar-pharma-world\/","title":{"rendered":"\u2018Multi-node supply chains\u2019 are the future, in a \u2018multi-polar pharma world\u2019"},"content":{"rendered":"
\"Counterfeit<\/div>\n

\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t

China, India, and the Middle East are all playing their role in shifting the geographical centre of production and innovation, the three regions emerging as particularly important to the global pharmaceutical supply chain<\/p>\n

Frank van Gelder, secretary general of Pharma.Aero, said a fracturing of the supply chain with a more geographically diffuse network of production, healthcare providers, and clinical centres could create new opportunities for airfreight and specialist logistics providers.<\/p>\n

\u201cChina is no longer only a major source of pharmaceutical ingredients and manufacturing capacity; it is becoming an increasingly important centre for biotechnology, clinical development, and innovative medicines,\u201d he told \u8f7d\u661f<\/em>.<\/p>\n

\u201cIndia remains essential to generics and manufacturing, while expanding its innovative capabilities; Europe and North America remain central, but innovation and production are becoming more geographically distributed.<\/p>\n

While Europe and North America would remain important pharma centres, he said the emergence of additional innovation and production hubs was creating what he called a \u201cmulti-polar pharmaceutical world\u201d.<\/p>\n

For logistics providers,\u00a0\u201cthat means multi-node supply chains \u2013 interconnected manufacturing sites, clinical centres, specialised logistics hubs, and healthcare delivery points, rather than dependence on a few dominant origins and gateways\u201d, Mr van Gelder explained.<\/p>\n

\u201cFor air cargo this opens opportunities for new regional gateways and specialised corridors, but it also demands much better network orchestration,\u201d he added. However, he cautioned that nodes must be \u201cqualified, connected, interoperable, and economically justified\u201d.<\/p>\n

That meant those considering it needed to be able to distinguish between diversification and \u201cexpensive duplication\u201d, he said, noting:\u201cMore nodes do not automatically mean greater resilience, more tonnage, or better profitability.\u201d<\/p>\n

And he warned that the emergence of regional gateways and specialised corridors would place greater demands on the ability of logistics operators to coordinate, given the increased complexity in these international networks.<\/p>\n

The requirement for temperature-controlled infrastructure, qualified handling facilities, and reliable connections between different supply chain participants was particularly important as pharmaceutical products become more specialised, he added.<\/p>\n

Mr van Gelder said: \u201cThe most profound change comes with advanced therapies. In autologous cell therapy, a patient\u2019s cells can be collected, transported for manufacturing, and returned as a personalised treatment.<\/p>\n

\u201cChain of identity, chain of custody, time, temperature, and clinical scheduling become inseparable. A disruption can affect a treatment appointment. Radioligand therapies introduce another set of highly time-sensitive, product-specific constraints,\u201d he said.<\/p>\n

However, Mr van Gelder cautioned against assuming the emergence of new pharmaceutical production centres or growth in innovative medicines would automatically translate into greater airfreight volumes.<\/p>\n